Clinical trials: Clinical Benefit Rate
Progression-free Survival, Overall Survival
Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades.
- Conditions
- Progression-free Survival, Overall Survival, Clinical Benefit Rate, Toxicity
- Trial name
- APFAO (NCT03359018)
- Testing
- Apatinib, SHR-1210
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Peking University People's Hospital
Hormone Receptor Positive Breast Cancer
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)
This phase II, open-label, single-arm, study investigates the clinical benefit of everolimus combined with endocrine therapy (ET) in hormone receptor-positive (HR+), metastatic breast cancer (MBC) patients who progressed on prior…
- Trial name
- MBC (NCT07646171)
- Testing
- Everolimus (Afinitor) tablets with endocrine therapy, Blood draw for biomarker and genetic analysis
- Where
- Israel
- Volunteers
- 19 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Prostate Cancer Metastatic, Metastasis
Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel
Rationale: The aim of this study is to identify the optimal second line treatment option for patients with a poor prognosis metastasized Castration Resistant Prostate Cancer (mCRPC) with respect to Clinical Benefit Rate (CBR)…
- Trial name
- OSTRICh (NCT03295565)
- Testing
- Cabazitaxel, Abiraterone, Enzalutamide
- Where
- 19 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
Ovarian Cancer, Carcinosarcoma
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
This study is a phase II, multi-centre, open label study in patients with advanced ovarian cancer. The treatment being tested is Pamiparib, with daily dosing.
- Trial name
- PRECISE (NCT03933761)
- Testing
- Pamiparib
- Sponsor
- Australia New Zealand Gynaecological Oncology Group
Infertility of Uterine Origin
Clinical Study of PGT-A Versus PGT-A+ERA
Patients who have shown previous implantation failures, despite transferring good quality and chromosomally normal embryos (diagnosed by PGT-A), could have a displaced Window of Implantation (WOI) and consequently, alterations in…
- Trial name
- PGT-A&ERA (NCT03530254)
- Testing
- PGT-A, ERA Test
- Where
- 15 sites in United States, Argentina and 10 more
- Volunteers
- 368 people
- Sponsor
- Igenomix
Rotator Cuff Disease
Establishing Clinical Significance in Rotator Cuff Disease
The goal of this observational study is to learn about rotator cuff patients. The main questions it aims to answer are: What is the minimal clinically important difference value of the Shoulder Disability Questionnaire, the short…
- Trial name
- NCT06677320
- Testing
- Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 69 people
- Sponsor
- Kırklareli University